Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome.

Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome.
复制标题

DOI:
10.1038/bcj.2013.74
复制
发表时间:
2014-01-17
影响因子:
12.8
通讯作者:
Tien, H-F
Tien, H-F
中科院分区:
医学1区
文献类型:
--
作者:
Chen, T-C;Hou, H-A;Chou, W-C;Tang, J-L;Kuo, Y-Y;Chen, C-Y;Tseng, M-H;Huang, C-F;Lai, Y-J;Chiang, Y-C;Lee, F-Y;Liu, M-C;Liu, C-W;Liu, C-Y;Yao, M.;Huang, S-Y;Ko, B-S;Hsu, S-C;Wu, S-J;Tsay, W.;Chen, Y-C;Tien, H-F

文献摘要

参考文献

被引文献

相似文献

最近,在骨髓增生异常综合征(MDS)患者中发现了额外性梳状1(ASXL1)基因的突变,但该突变与其他基因改变的相互作用及其在疾病进展过程中的动态变化仍有待确定。在这项研究中,根据法国-美国-英国 (FAB) 分类,在 466 名原发性 MDS 患者中,有 106 名 (22.7%) 被鉴定出 ASXL1 突变;根据世界卫生组织 (WHO) 分类,在 362 名原发性 MDS 患者中,有 62 名 (17.1%) 被鉴定出 ASXL1 突变。 ASXL1突变与8三体以及RUNX1、EZH2、IDH、NRAS、JAK2、SETBP1和SRSF2突变密切相关,但与SF3B1突变呈负相关。大多数 ASXL1 突变患者 (85%) 在诊断时同时存在其他基因突变。 ASXL1 突变是生存的独立不良预后因素。后续研究表明,在所有 32 名 ASXL1 突变患者中,原始 ASXL1 突变在疾病进展时保持不变,但经常伴有其他基因突变的获得,包括 RUNX1、NRAS、KRAS、SF3B1、SETBP1 和染色体进化。另一方面,在80名ASXL1野生患者中,只有一名在白血病转化时获得了ASXL1突变。总之,与其他基因改变相关的 ASXL1 突变可能在 MDS 的发展中发挥作用,但对疾病进展影响不大。
Recently, mutations of the additional sex comb-like 1 (ASXL1) gene were identified in patients with myelodysplastic syndrome (MDS), but the interaction of this mutation with other genetic alterations and its dynamic changes during disease progression remain to be determined. In this study, ASXL1 mutations were identified in 106 (22.7%) of the 466 patients with primary MDS based on the French-American-British (FAB) classification and 62 (17.1%) of the 362 patients based on the World Health Organization (WHO) classification. ASXL1 mutation was closely associated with trisomy 8 and mutations of RUNX1, EZH2, IDH, NRAS, JAK2, SETBP1 and SRSF2, but was negatively associated with SF3B1 mutation. Most ASXL1-mutated patients (85%) had concurrent other gene mutations at diagnosis. ASXL1 mutation was an independent poor prognostic factor for survival. Sequential studies showed that the original ASXL1 mutation remained unchanged at disease progression in all 32 ASXL1-mutated patients but were frequently accompanied with acquisition of mutations of other genes, including RUNX1, NRAS, KRAS, SF3B1, SETBP1 and chromosomal evolution. On the other side, among the 80 ASXL1-wild patients, only one acquired ASXL1 mutation at leukemia transformation. In conclusion, ASXL1 mutations in association with other genetic alterations may have a role in the development of MDS but contribute little to disease progression.
DOI: 10.1158/0008-5472.can-09-3783
发表时间: 2010-01-15
期刊: Cancer research
影响因子: 11.2
作者:
Abdel-Wahab O;Manshouri T;Patel J;Harris K;Yao J;Hedvat C;Heguy A;Bueso-Ramos C;Kantarjian H;Levine RL;Verstovsek S
通讯作者: Verstovsek S
DOI: 10.1158/0008-5472.can-05-4316
发表时间: 2006-03-15
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Chou, WC;Tang, JL;Tien, HF
通讯作者: Tien, HF
DOI: 10.1016/j.ccr.2012.06.032
发表时间: 2012-08-14
期刊: Cancer cell
影响因子: 50.3
作者:
Abdel-Wahab O;Adli M;LaFave LM;Gao J;Hricik T;Shih AH;Pandey S;Patel JP;Chung YR;Koche R;Perna F;Zhao X;Taylor JE;Park CY;Carroll M;Melnick A;Nimer SD;Jaffe JD;Aifantis I;Bernstein BE;Levine RL
通讯作者: Levine RL
DOI: 10.1038/leu.2010.267
发表时间: 2011-02-01
期刊: LEUKEMIA
影响因子: 11.4
作者:
Chou, W-C;Lei, W-C;Tien, H-F
通讯作者: Tien, H-F
DOI: 10.1182/blood-2009-11-253070
发表时间: 2010-04-08
期刊: BLOOD
影响因子: 20.3
作者:
Chou, Wen-Chien;Hou, Hsin-An;Tien, Hwei-Fang
通讯作者: Tien, Hwei-Fang